Literature DB >> 15955099

Additional evidence that pityriasis rosea is associated with reactivation of human herpesvirus-6 and -7.

Francesco Broccolo1, Francesco Drago, Anna M Careddu, Chiara Foglieni, Laura Turbino, Clementina E Cocuzza, Carlo Gelmetti, Paolo Lusso, Alfredo E Rebora, Mauro S Malnati.   

Abstract

To elucidate the role of human herpesvirus (HHV)-6 and -7 (HHV-7) in pityriasis rosea (PR), we measured their DNA load in plasma, peripheral blood mononuclear cells (PBMC), and tissues using a calibrated quantitative real-time PCR assay. We also studied HHV-6- and HHV-7-specific antigens in skin by immunohistochemistry and anti-HHV-7 neutralizing activity using a syncytia-inhibition test. Plasma and PBMC were obtained from 31 PR patients (14 children, 17 adults), 12 patients with other dermatites, and 36 blood donors. Skin biopsies were obtained from 15 adults with PR and 12 with other dermatites. HHV-6 and HHV-7 DNA were detected in 17% and in 39% of PR plasmas, respectively, but in no controls. HHV-7 viremia was associated with a higher PBMC load and, in adults, with systemic symptoms. HHV-7, but not HHV-6, levels in PBMC were higher in PR patients than in controls. HHV-6 and HHV-7 antigens were found only in PR skin (17% and 67% of patients analyzed, respectively), indicating a productive infection. Syncytia-neutralizing antibodies were found in PR patients and controls, but their titers were lower in patients with HHV-7 viremia. These data confirm the causal association between PR and active HHV-7 or, to a lesser extent, HHV-6 infection.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15955099     DOI: 10.1111/j.0022-202X.2005.23719.x

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  36 in total

1.  [Pityriasis rosea in myocarditis].

Authors:  Ruediger Stephan Goertz; Wolfgang Klotzek
Journal:  Med Klin (Munich)       Date:  2010-02

2.  Pityriasis rosea in chronic hepatitis C.

Authors:  Viroj Wiwanitkit
Journal:  Balkan Med J       Date:  2014-12-01       Impact factor: 2.021

Review 3.  Human herpesviruses 6, 7, and 8 from a dermatologic perspective.

Authors:  Michael M Wolz; Gabriel F Sciallis; Mark R Pittelkow
Journal:  Mayo Clin Proc       Date:  2012-07-21       Impact factor: 7.616

4.  Pityriasis rosea-like eruption associated with ondansetron use in pregnancy.

Authors:  Malak M Alame; Dina J Chamsy; Hassan Zaraket
Journal:  Br J Clin Pharmacol       Date:  2018-03-09       Impact factor: 4.335

5.  Interventions for pityriasis rosea.

Authors:  Jose Contreras-Ruiz; Sandra Peternel; Carlos Jiménez Gutiérrez; Ivana Culav-Koscak; Ludovic Reveiz; Maria de Lourdes Silbermann-Reynoso
Journal:  Cochrane Database Syst Rev       Date:  2019-10-30

6.  Concurrent pityriasis rosea and Bell's palsy.

Authors:  Vanessa Voss; Adam Mattox; Mary Guo
Journal:  BMJ Case Rep       Date:  2017-01-23

7.  The comparison between the efficacy of high dose acyclovir and erythromycin on the period and signs of pitiriasis rosea.

Authors:  Amirhooshang Ehsani; Nafiseh Esmaily; Pedram Noormohammadpour; Siavash Toosi; Alireza Hosseinpour; Mahbobeh Hosseini; Shima Sayanjali
Journal:  Indian J Dermatol       Date:  2010 Jul-Sep       Impact factor: 1.494

8.  A Randomized, Double-blind, Placebo-Controlled Study of Efficacy of Oral Acyclovir in the Treatment of Pityriasis Rosea.

Authors:  Satyaki Ganguly
Journal:  J Clin Diagn Res       Date:  2014-05-15

9.  Pityriasis rosea like drug rash - a need to identify the disease in childhood.

Authors:  Maitreyee Panda; Nibedita Patro; Monalisa Jena; Mrutunjay Dash; Swati Mishra
Journal:  J Clin Diagn Res       Date:  2014-08-20

10.  Entire genome characterization of human papillomavirus type 16 from infected Thai women with different cytological findings.

Authors:  Woradee Lurchachaiwong; Pairoj Junyangdikul; Sunchai Payungporn; Jira Chansaenroj; Pichet Sampathanukul; Damrong Tresukosol; Wichai Termrungruanglert; Apiradee Theamboonlers; Yong Poovorawan
Journal:  Virus Genes       Date:  2009-05-03       Impact factor: 2.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.